An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Daratumumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 23 Jul 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to PI request
- 14 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.
- 14 May 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jul 2020.